OncoMatch/Clinical Trials/NCT05451771
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Is NCT05451771 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for al amyloidosis.
Treatment: Venetoclax Oral Tablet, 200 mg · FISH assay · Venetoclax Oral Tablet, 400 mg · Dexamethasone Oral, 10 mg · Dexamethasone Oral, 20 mg · Daratumumab · Bendamustine · Pomalidomide · Ixazomib · Venetoclax MTD with Dexamethasone — The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: CCND1 t(11;14) translocation
Disease stage
Excluded: Stage MAYO STAGE THREE-B (IIIB) WITH NT-PRO BNP > 8500 PG/ML
Mayo stage three-B (IIIB) with N-terminal pro-hormone B-type natriuretic peptide (NT-Pro BNP) > 8500 pg/mL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD38 monoclonal antibody
Has received ≥1 prior lines of therapy, including an anti-cluster of differentiation 38 (CD 38) monoclonal antibody
Cannot have received: BCL2 inhibitor
Prior exposure to anti-apoptotic protein B-cell lymphoma 2 (BCL-2) inhibitors
Lab requirements
Cardiac function
New York Heart Association (NYHA) Class III or IV heart failure [excluded]
Patients on renal replacement therapy; New York Heart Association (NYHA) Class III or IV heart failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Boston Medical Center · Boston, Massachusetts
- Mayo Clinic Rochester · Rochester, Minnesota
- New York Presbyterian Hospital/Columbia University Irving Medical Center · New York, New York
- Froedtert Hospital & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05451771 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCL2 inhibitor disqualifies patients from enrollment.
Does this trial require CCND1?
Yes, CCND1 t(11;14) translocation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages